Search

Your search for "nmrd" returned the following results.
Filter Results:
News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market

November 18, 2021

The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives According to a recent […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2 2022 Financial, Business Report

November 15, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has reported its financial and business updates for the second quarter of FY2022, the period ended Sept. 30, 2021. Notable highlights include the launch of Miboko, the company’s beta mass-market metabolic health […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market

November 9, 2021

Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The MiBoKo application is designed to measure and monitor the user’s metabolic health scores based on glucose tolerance and insulin resistance. […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Participation at Diabetes Technology Society Conference

November 4, 2021

Nemaura Medical (NASDAQ: NMRD) CEO Faz Chowdhury, PhD, will be presenting at annual meeting of the Diabetes Technology Society. The two-day meeting is slated for Nov. 5–6, 2021, with virtual workshops on Thursday, Nov. 4; Chowdury’s presentation is scheduled for Nov. 4,  at 2 p.m. ET. The aim of the Diabetes Technology Society meeting is […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Stands Distinct in Patient Support

October 28, 2021

Nemaura Medical (NASDAQ: NMRD), a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, pays close attention to essential information and research that impacts the successful implementation of its solutions. Recently, the company tweeted about a study published by Dove Medical Press that included a survey of 105 participants with […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Facilitating Improved Diabetes and Prediabetes Management

October 22, 2021

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing diagnostic devices and supporting personalized lifestyle coaching programs. Its flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible continuous glucose monitor designed to help people with diabetes and prediabetes manage their glucose levels. “Over 420 million people globally are currently living with diabetes, […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Announce Beta Launch of Proprietary ‘MiBoKo’ Metabolic Health Program

October 18, 2021

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the beta launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores US diabetes-related healthcare expenditures totalled $760 billion in 2019 alone, equating to an annual spend of over […]

InvestorNewsBreaks

InvestorNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

October 15, 2021

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Harnesses the Power of Patient-Provider Communication

October 6, 2021

NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits Better communication between patients and their healthcare providers impacts adherence to prescribed treatment According to a report published in […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming LD Micro Main Event

October 5, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be featured at the 14th annual LD Micro Main Event conference; the conference will be a virtual event. As part of the company’s presence at the conference, […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Beta Launch of MiBoKo

September 29, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. According to the update, Nemaura’s Chief Executive Officer Dr. […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real time glucose measurements and daily glucose trend […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Reveals Attendance at This Year’s H.C. Wainwright Global Investment Conference

September 27, 2021

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021 Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription […]

Press Releases

Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function

September 24, 2021

NEW YORK, Sept. 24, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio — Nemaura Medical Inc. (NASDAQ: NMRD) announces the availability of a broadcast titled, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity.” To hear the AudioPressRelease, please visit The NetworkNewsAudio News Podcast. To view the full editorial, please visit https://nnw.fm/aKQpJ. Globally, 463 million people have diabetes. […]

Press Releases

Nemaura Medical Inc. (NASDAQ: NMRD) Offers Sought-After Solutions in Areas of Unmet Medical Need

September 22, 2021

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Nemaura Medical Inc. (NASDAQ: NMRD) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Benzinga Healthcare Small Cap Conference

September 21, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present at the Benzinga Healthcare Small Cap Conference. The event is slated to be held virtually from Sept. 29 – 30, 2021. […]

InvestorNewsBreaks

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names World-Renowned Thought Leader as Advisory Board Member

September 17, 2021

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes […]

News Articles

Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetes sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDA Nemaura continues to […]

News Articles

Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) Target Diabetes Tech

October 26, 2021

The world’s largest and most powerful tech companies –Alphabet (NASDAQ: GOOG), Amazon (NASDAQ: AMZN) and Apple (NASDAQ: AAPL) – are targeting an opportunity in health care that’s just too big to ignore – diabetes. Almost a third of the entire U.S. population – more than 100 million people in this country alone – are living […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).